Inhibition of ileal apical but not basolateral bile acid transport reduces atherosclerosis in apoE-/- mice

Atherosclerosis

Volumn 229, Issue 2, 2013, Pages 374-380

  Lan, Tian ^a   Haywood, Jamie ^a   Dawson, Paul A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

ApoE knockout mouse; Atherosclerosis; Bile acids; Cholesterol; Fibroblast growth factor 15; Ileum; Transporters

Indexed keywords

APOLIPOPROTEIN E; BILE ACID; CHOLESTEROL 7ALPHA MONOOXYGENASE; CHOLESTEROL ESTER; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; BASOLATERAL MEMBRANE; BILE ACID METABOLISM; BILE ACID SYNTHESIS; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; ENTEROHEPATIC CIRCULATION; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOE KNOCKOUT MOUSE; ATHEROSCLEROSIS; BILE ACIDS; CHOLESTEROL; FIBROBLAST GROWTH FACTOR 15; ILEUM; TRANSPORTERS;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BILE ACIDS AND SALTS; CELL POLARITY; CHOLESTEROL; CHOLESTEROL 7-ALPHA-HYDROXYLASE; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLAST GROWTH FACTORS; ILEUM; LIVER; MALE; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; RECEPTORS, LDL; SYMPORTERS; TRIGLYCERIDES;

EID: 84880399620     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.05.017     Document Type: Article

References (43)

1. Dawson P.A. Bile formation and the enterohepatic circulation. Physiology of the gastrointestinal tract 2012, 1461-1484. Academic Press, Oxford. 5th ed. L.R. Johnson (Ed.).
2. Dietschy J.M., Turley S.D., Spady D.K. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. JLipid Res 1993, 34:1637-1659.
3. Packard C.J., Shepherd J. The hepatobiliary axis and lipoprotein metabolism: effects of bile acid sequestrants and ileal bypass surgery. JLipid Res 1982, 23:1081-1098.
4. Out C., Groen A.K., Brufau G. Bile acid sequestrants: more than simple resins. Curr Opin Lipidol 2012, 23:43-55.
5. Huff M.W., Telford D.E., Edwards J.Y., et al. Inhibition of the apical sodium-dependent bile acid transporter reduces LDL cholesterol and apoB by enhanced plasma clearance of LDL apoB. Arterioscler Thromb Vasc Biol 2002, 22:1884-1891.
6. Root C., Smith C.D., Sundseth S.S., Pink H.M., Wilson J.G., Lewis M.C. Ileal bile acid transporter inhibition, CYP7A1 induction, and antilipemic action of 264W94. JLipid Res 2002, 43:1320-1330.
7. Buchwald H., Varco R.L., Matts J.P., et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). NEngl J Med 1990, 323:946-955.
8. Dawson P.A., Lan T., Rao A. Bile acid transporters. JLipid Res 2009, 50:2340-2357.
9. Rao A., Haywood J., Craddock A.L., Belinsky M.G., Kruh G.D., Dawson P.A. The organic solute transporter alpha-beta, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis. Proc Natl Acad Sci U S A 2008, 105:3891-3896.
10. Ballatori N., Fang F., Christian W.V., Li N., Hammond C.L. Ostalpha-Ostbeta is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver. Am J Physiol Gastrointest Liver Physiol 2008, 295:G179-G186.
11. Dawson P.A., Haywood J., Craddock A.L., et al. Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. JBiol Chem 2003, 278:33920-33927.
12. Lundasen T., Andersson E.M., Snaith M., et al. Inhibition of intestinal bile acid transporter Slc10a2 improves triglyceride metabolism and normalizes elevated plasma glucose levels in mice. PLoS One 2012, 7:e37787.
13. Lan T., Rao A., Haywood J., Kock N.D., Dawson P.A. Mouse organic solute transporter alpha deficiency alters FGF15 expression and bile acid metabolism. JHepatol 2012, 57:359-365.
14. Inagaki T., Choi M., Moschetta A., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005, 2:217-225.
15. Kong B., Wang L., Chiang J.Y., Zhang Y., Klaassen C.D., Guo G.L. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 2012, 56:1034-1043.
16. Lee R.G., Kelley K.L., Sawyer J.K., Farese R.V., Parks J.S., Rudel L.L. Plasma cholesteryl esters provided by lecithin:cholesterol acyltransferase and acyl-coenzyme a:cholesterol acyltransferase 2 have opposite atherosclerotic potential. Circ Res 2004, 95:998-1004.
17. Jung D., Inagaki T., Gerard R.D., et al. FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. JLipid Res 2007, 48:2693-2700.
18. Terasaka N., Miyazaki A., Kasanuki N., et al. ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice. Atherosclerosis 2007, 190:239-247.
19. Meissner M., Wolters H., de Boer R.A., et al. Bile acid sequestration normalizes plasma cholesterol and reduces atherosclerosis in hypercholesterolemic mice. No additional effect of physical activity. Atherosclerosis 2013, 228:117-123.
20. Galman C., Ostlund-Lindqvist A.M., Bjorquist A., et al. Pharmacological interference with intestinal bile acid transport reduces plasma cholesterol in LDL receptor/apoE deficiency. Faseb J 2003, 17:265-267.
21. -/- mice by SC-435. JLipid Res 2003, 44:1614-1621.
22. Braun A., Yesilaltay A., Acton S., et al. Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice. Atherosclerosis 2007, 198:77-84.
23. Oelkers P., Kirby L.C., Heubi J.E., Dawson P.A. Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). JClin Invest 1997, 99:1880-1887.
24. Li T., Matozel M., Boehme S., et al. Overexpression of cholesterol 7alpha-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis. Hepatology 2011, 53:996-1006.
25. Miyake J.H., Duong-Polk X.T., Taylor J.M., et al. Transgenic expression of cholesterol-7-alpha-hydroxylase prevents atherosclerosis in C57BL/6J mice. Arterioscler Thromb Vasc Biol 2002, 22:121-126.
26. Post S.M., Groenendijk M., van der Hoogt C.C., et al. Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background increases hepatic ABCA1 mRNA expression and HDL-cholesterol. Arterioscler, Thromb Vasc Biol 2006, 26:2724-2730.
27. Erickson S.K., Lear S.R., Deane S., et al. Hypercholesterolemia and changes in lipid and bile acid metabolism in male and female cyp7A1-deficient mice. JLipid Res 2003, 44:1001-1009.
28. Pullinger C.R., Eng C., Salen G., et al. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. JClin Invest 2002, 110:109-117.
29. Gaw A., Packard C.J., Lindsay G.M., Collins S.M., Lorimer A.R., Shepherd J. Metabolism of apolipoprotein B in primary moderate hypercholesterolaemia: effects of acipimox and cholestyramine therapy. Eur J Med Res 1995, 1:38-48.
30. Gaw A., Packard C.J., Lindsay G.M., et al. Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism. Arteriosclerosis, Thromb Vasc Biol 1996, 16:236-249.
31. Rudling M., Angelin B. Growth hormone reduces plasma cholesterol in LDL receptor-deficient mice. FASEB J Off Publ Fed Am Societies Exp Biol 2001, 15:1350-1356.
32. Evans M.J., Mahaney P.E., Borges-Marcucci L., et al. Asynthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol 2009, 296:G543-G552.
33. Zhang Y., Lee F.Y., Barrera G., et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 2006, 103:1006-1011.
34. -/- mice. Arterioscler Thromb Vasc Biol 2006, 26:2316-2321.
35. Watanabe M., Houten S.M., Wang L., et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. JClin Invest 2004, 113:1408-1418.
36. Herrema H., Meissner M., van Dijk T.H., et al. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptor alpha-controlled metabolic pathways in mice. Hepatology 2010, 51:806-816.
37. Kast H.R., Nguyen C.M., Sinal C.J., et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol 2001, 15:1720-1728.
38. Lundasen T., Galman C., Angelin B., Rudling M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. JIntern Med 2006, 260:530-536.
39. Galman C., Angelin B., Rudling M. Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19. JIntern Med 2011, 270:580-588.
40. Wu X., Ge H., Baribault H., et al. Dual actions of fibroblast growth factor 19 on lipid metabolism. JLipid Res 2013, 54:325-332.
41. Watanabe M., Morimoto K., Houten S.M., et al. Bile acid binding resin improves metabolic control through the induction of energy expenditure. PLoS One 2012, 7:e38286.
42. Potthoff M.J., Boney-Montoya J., Choi M., et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab 2011, 13:729-738.
43. Wu A.L., Coulter S., Liddle C., et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One 2011, 6:e17868.